Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2015-01-19 Regulatory Filings
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Merger between OnCore and Tekmira includes development of NVP018 for the treatment of Hepatitis B
Regulatory Filings Classification · 1% confidence The document is structured as a 'NEWS RELEASE' from NeuroVive Pharmaceutical AB, dated January 19, 2015. It contains updates on multiple drug candidates (NVP018, CicloMulsion®, NeuroSTAT®, NVP019) and reports on corporate activities, specifically a merger involving a licensee (OnCore/Tekmira) and the status of ongoing clinical trials. This format, which provides periodic operational and pipeline updates rather than comprehensive annual financials (10-K) or specific regulatory filings like insider trades (DIRS) or dividend notices (DIV), strongly suggests an Investor Relations communication. Since it details the status of projects and corporate events, it is best classified as an Investor Presentation (IP) if it were a slide deck, or more generally, a type of Investor Relations material. Given the options, this comprehensive update covering multiple projects and corporate news aligns most closely with the content typically found in an Investor Presentation (IP) or a detailed press release that serves an investor update function. However, looking strictly at the definitions, it is a general announcement of corporate and project status. It is not a formal financial report (10-K, IR), a transcript (CT), or a specific transaction report (POS, DIRS). Since it provides detailed status updates on R&D projects and corporate milestones, 'Investor Presentation' (IP) is the closest fit for a detailed, non-financial-statement update aimed at investors, although 'Regulatory Filings' (RNS) is a possible fallback. Given the depth of project status updates, IP is preferred over the generic RNS.
2015-01-19 English
Årsstämman tidigareläggs till den 30 mars 2015
AGM Information Classification · 1% confidence The document is a press release dated January 12, 2015, announcing that the Annual General Meeting (Årsstämman) for NeuroVive Pharmaceutical AB has been moved to March 30, 2015. It details deadlines for shareholder proposals and information regarding the nomination committee. Since the core subject is the scheduling and logistics related to the Annual General Meeting, the most appropriate classification is AGM Information (AGM-R). It is not the meeting materials themselves, but an announcement directly pertaining to the AGM.
2015-01-12 Swedish
Annual General Meeting brought forward to March 30 2015
Report Publication Announcement Classification · 1% confidence The document is a press release dated 2015-01-12 announcing that the Annual General Meeting (AGM) for NeuroVive Pharmaceutical AB has been brought forward to March 30, 2015. It provides details on shareholder proposal deadlines for the AGM and Nomination Committee. This content directly relates to the scheduling and administrative aspects of the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (3235 chars) is short, but it is not merely announcing the publication of a full AGM package; it is the primary announcement regarding the meeting's date change and related procedures.
2015-01-12 English
NeuroVive har anställt en Clinical Trial Manager
Board/Management Information Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and announces a specific operational event: the hiring of a Clinical Trial Manager. It details the new hire's background and the strategic reason for the recruitment (supporting ongoing clinical trials and expansion). This type of announcement, concerning personnel changes at the management or key operational level, aligns best with the 'Board/Management Information' category (MANG). While it is a press release, the content is specific to management/personnel, not a general regulatory filing (RNS) or a report publication announcement (RPA). The document length (3980 chars) is substantial enough to contain the core information, making it the announcement itself, not just a notice of an attachment.
2014-12-08 Swedish
NeuroVive employs a Clinical Trial Manager
Board/Management Information Classification · 1% confidence The document is a short press release dated December 8, 2014, announcing the recruitment of a Clinical Trial Manager. It details personnel changes and provides a brief 'About' section for the company. This type of announcement, concerning changes in senior management or board composition, directly aligns with the definition of 'Board/Management Information' (MANG). It is not a formal financial report (like 10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A). Given the content focuses on a key management hire, MANG is the most appropriate classification.
2014-12-08 English
NeuroVive and Skåne University Hospital initiate collaboration on clinical phase II study on kidney protection during heart surgery
Earnings Release Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces a collaboration and the initiation of a clinical phase II study regarding the product CicloMulsion®. It provides key highlights, context on the medical need, and updates on other drug candidates (NeuroSTAT®, NVP019, NVP018). This structure—a brief announcement of significant operational/clinical news rather than a comprehensive financial report (like 10-K or IR) or a full transcript—is characteristic of an Earnings Release (ER) or a general press release. Since it focuses on operational/clinical milestones rather than just financial results, and given the options, it fits best as an Earnings Release (ER) which often includes operational updates, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure not covered elsewhere. However, the content strongly suggests an announcement of material, non-financial operational news, which often accompanies or substitutes for a formal ER in biotech/pharma contexts, or is classified as a general operational update. Given the options, 'ER' (Earnings Release) is the closest fit for a major company announcement detailing clinical progress and pipeline status, even if it's not strictly quarterly financials. If it were purely a regulatory filing without specific financial results, RNS would be considered, but ER covers major operational announcements well. FY 2014
2014-12-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.